In parallel, the study of the biological processes underlying CLL pathogenesis has profoundly changed the treatment landscape of this disease, leading to the striking development of targeted therapies such as BCR signaling or BCL2 inhibitors, almost completely displacing chemotherapy-based regimens from the treatment algorithms nowadays [3,16]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.